Recent Trends in Atherosclerosis and Related Diseases

Atherosclerosis is a multifactorial disease that affects large arteries and causes much morbidity and mortality worldwide. Despite ongoing research for several decades, it is still a global health problem that cannot be stopped and cured completely. Furthermore, the development of this disease is contributed to by various processes, primarily disturbances in cholesterol metabolism, local low-grade inflammation, and oxidative stress, resulting in the formation of atherosclerotic plaques. In this work, a stochastic Petri net model was constructed and subsequently analyzed to examine the impact of these factors on the development and progression of atherosclerosis. The use of knockout- and simulation-based analysis allowed for a comprehensive investigation of the studied phenomena. Our research has demonstrated that while cholesterol is a contributing factor in atherosclerosis, blocking its impact alone is insufficient in halting the progression of this disorder. Inhibition of oxidative stress is also important when blocking the impact of phosphoprotein phosphatase inhibitor-1 (PPI-1), microsomal triglyceride transfer protein (MTTP), and 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMGCR), as our model shows that this action reduces the number of foam cells underlying atherosclerosis. The results obtained further support the previous observations that the combined treatment is significantly effective in enhancing therapeutic efficacy against atherosclerosis. Full article

A new method was developed for the simultaneous determination of vascular endothelial growth factor (VEGF-A) and fibroblast growth factor-2 (FGF-2) in blood serum, using biosensors with array Surface Plasmon Resonance imaging (SPRi) detection. It can be applied as a single method for simultaneous VEGF-A and FGF-2 determination or as two separate methods for testing only one selected protein in each case. Validation was carried out for each method. Limit of detection (LOD) and limit of quantification (LOQ) values were determined and were found not to differ significantly from the parameters obtained in comparisons with commercial enzyme-linked immunosorbent assay (ELISA) tests. Tests were carried out to check the robustness of the method. The results indicate a lack of robustness of the analytical method to elevated temperature and pH values other than those recommended by the manufacturers of the reagents (recommended pH = 7.40). The values of recoveries were determined and confirmed the reliability of the results obtained with the use of the newly developed method. The selectivity studies showed no negative influence of other proteins present in the matrix of the tested samples on the results of the VEGF-A and FGF-2 concentration measurements. The developed method is also characterized by high reproducibility of the results obtained and agreement with the VEGF-A and FGF-2 concentration values obtained with commercial ELISA tests. The proposed method offers fast, reproducible, and accurate simultaneous quantification of VEGF-A and FGF-2 in human body fluids. Only 4 µL of test sample are required for simultaneous analysis. The total time for simultaneous analysis of both biomarkers does not exceed 20 min. The developed analytical method is superior to ELISA in terms of analysis time and sample volume for analysis, and it offers lower LOD and LOQ values and allows for the simultaneous analysis of two biomarkers. There is also no need to collect a large number of samples. Standard ELISAs usually have 96 reaction wells. The proposed biosensor can be used to analyse only one sample, without the need to waste reagents on unused reaction sites. In addition, it is possible to regenerate the biosensor and reuse it. Full article